Navigation Links
Many NIH-funded clinical trials go unpublished over 2 years after completion
Date:1/3/2012

In a study that investigates the challenges of disseminating clinical research findings in peer-reviewed biomedical journals, Yale School of Medicine researchers have found that fewer than half of a sample of trials primarily or partially funded by the National Institutes of Health (NIH) were published within 30 months of completing the clinical trial.

These findings appear in the January issue of the British Medical Journal, which focuses on the topic of unpublished evidence.

"When research findings are not disseminated, the scientific process is disrupted and leads to redundant efforts and misconceptions about clinical evidence," said Joseph Ross, M.D., first author of the study and a Yale assistant professor of medicine. "Such inaction undermines both the trial in question and the evidence available in peer-reviewed medical literature. This has far-reaching implications for policy decisions, and even institutional review board assessments of risks and benefits associated with future research studies."

Ross and co-authors performed a cross-sectional analysis of NIH-funded clinical trials registered within ClinicalTrials.gov, a trial registry and results database maintained by the U.S. National Library of Medicine. All trials in the study sample were registered after September 30, 2005 and completed by December 31, 2008, allowing at least 30 months for publication following completion of the trial.

They found that overall fewer than half of NIH-funded trials in the sample were published in a peer-reviewed, MEDLINE-indexed biomedical journal within 30 months of trial completion. They also found that one-third of trials remained unpublished 51 months after completion.

Ross said that there may be many reasons for lack of publication, such as not getting accepted by a journal or not prioritizing the dissemination of research findings. Still, he said, there are alternative methods for providing timely public access to study results, including the results database at ClinicalTrials.gov that was created in response to Federal law.

"Steps must be taken to ensure the timely dissemination of publicly funded research so that data from all those who volunteer are available to inform future research and practice," Ross said.

While this study was focused on trials funded by NIH, Ross said that similar problems with non-publication and delayed publication of research findings have been described among trials funded by the pharmaceutical and medical device industries, as well as by non-profit organizations.

"This suggests that the current culture of research needs to prioritize the timely public dissemination of research findings, ideally via peer-reviewed journals, for research funded by both public and private sources," said Ross. "More work needs to be done to better understand impediments to publication."


'/>"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
Source:Eurekalert

Related medicine news :

1. NIH-funded scientists identify potential malaria drug candidates
2. NIH-funded twin study finds occupational chemical exposure may be linked to Parkinsons risk
3. NIH-funded research points to potential therapy for tumor-associated epilepsy
4. Traumatic brain injury: NIH-funded researchers will assess biomarkers for diagnosis and treatment
5. NIH-funded researchers find new ways to confuse blood-seeking mosquitoes
6. NIH-funded study finds new possible risk factor of heart disease
7. NIH-funded study uses new technology to peek deep into the brain
8. In NIH-funded study, researchers uncover step in brain events leading up to addiction
9. NIH-funded study finds early HAART during TB treatment boosts survival rate in co-infected people
10. University of Mississippi Medical Center to lead in nationwide NIH-funded Alzheimers study
11. NIH-funded scientists find 2009 H1N1 pandemic influenza vaccine protects mice from 1918 flu virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... HealthPostures, the desk for standing designer ... stand solutions representative to the Minneapolis Home and Garden Show which is being held ... is garnering national attention is the Minneapolis Convention Center. , From its broad ...
(Date:2/22/2017)... ... February 22, 2017 , ... When it came time to ... in Georgia, PENETRON Specialty Products (PSP) provided the solution. January’s grand opening presented ... $51 million to purchase and renovate the 185,000 square-foot office complex, which was ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem cell therapy ... The technology is so cutting edge, in fact, the U.S. Food and Drug ... procedures. However, successful patient outcomes in certain clinical stem cell procedures have shown ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... certification exam and eligibility requirements effective with the April 2017 testing period. NACCM, ... , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ensure ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... analytics to accurately understand each Medicare Advantage member’s risk, identify any gaps-in-coding, ... This new solution helps transform the HCC Risk Adjustment process from a ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... 23, 2017 Persistence Market ... global market for intraoperative imaging, excerpts from which ... US$ 513.9 million. According to the report, the ... the grounds of increasing adoption of minimally-invasive surgeries ... diagnostic imaging for neurosurgeries. The world,s leading medical ...
(Date:2/23/2017)... -- Research and Markets has announced the addition of ... Industry Forecast to 2025" report to their offering. ... The Global Cardiac Prosthetic ... 9.2% over the next decade to reach approximately $8.9 billion by ... forecasts for all the given segments on global as well as ...
(Date:2/23/2017)... 2017 MabVax Therapeutics Holdings, Inc ... company, announces that it has received notice from ... the initiation a Phase I clinical trial with ... MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s novel ... initiate the phase I clinical trial in patients ...
Breaking Medicine Technology: